Humacyte, Inc. Debt Instrument Issued Principal
Humacyte, Inc. (HUMA) reported Debt Instrument Issued Principal of $1.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:DebtInstrumentIssuedPrincipal · last filed 2026-08-12
- Humacyte, Inc. debt instrument issued principal for the quarter ending 2026-06-30 was $0.00.
- Humacyte, Inc. debt instrument issued principal for the quarter ending 2026-03-31 was $1.70M.
- Humacyte, Inc. debt instrument issued principal for fiscal 2025 was $1.70M.
| Period end | Debt Instrument Issued Principal 3 month | Debt Instrument Issued Principal 6 month | Debt Instrument Issued Principal 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.70M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $1.70M 10-Q · filed 2026-05-13 | ||
| 2025-12-31 | $1.70M 10-K · filed 2026-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |